Revenue: As of FY2026 Q2, the actual value is USD 0.EPS: As of FY2026 Q2, the actual value is USD -0.3.EBIT: As of FY2026 Q2, the actual value is USD -995.46 K, beating the estimate of USD -2.5 M.<h3>Segment Revenue</h3><ul><li>The company did not generate any revenue during the three and six months ended October 31, 2025 and 2024, and does not anticipate generating revenue for the foreseeable future.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended October 31, 2025, the net loss was $1,000,758, a decrease from $1,361,563 in the same period in 2024. For the six months ended October 31, 2025, the net loss was $3,703,442, compared to $2,335,974 in the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended October 31, 2025 were $998,109, a decrease from $1,358,068 in the same period in 2024. For the six months ended October 31, 2025, total operating expenses were $3,698,310, compared to $2,320,473 in the same period in 2024.</li><li>Research and Development Expenses: For the three months ended October 31, 2025, research and development expenses were $176,283, a decrease from $311,088 in the same period in 2024. For the six months ended October 31, 2025, research and development expenses were $1,917,150, compared to $517,659 in the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended October 31, 2025, general and administrative expenses were $821,826, a decrease from $1,046,980 in the same period in 2024. For the six months ended October 31, 2025, general and administrative expenses were $1,781,160, compared to $1,802,814 in the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities for the six months ended October 31, 2025 was $3,534,225, compared to $4,455,843 in the same period in 2024.</li><li>Free Cash Flow: Not explicitly stated, but the net increase in cash and cash equivalents for the six months ended October 31, 2025 was $500,775, compared to $3,717,025 in the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation Expense: For the three months ended October 31, 2025, stock-based compensation expense was $31,514, a decrease from $81,277 in the same period in 2024. For the six months ended October 31, 2025, stock-based compensation expense was $74,416, compared to $162,554 in the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance clinical development of AL001 for Alzheimer’s, BD, MDD, and PTSD treatment, and ALZN002 for Alzheimer’s treatment. It aims to expand its pipeline to include additional indications for AL001 and optimize the value of AL001 and ALZN002 in major markets.</li><li>Non-Core Business: The company is focused on translational and functional endpoints to efficiently develop product candidates.</li><li>Priority: The company emphasizes the need to raise additional capital to fund its operations and clinical trials, with plans to seek funding through public equity, private equity, and debt financings.</li></ul>

Alzamend Neuro | 10-Q: FY2026 Q2 Revenue: USD 0